HAVN Life Sciences Inc., a biotechnology company, engages in the research and development of psychopharmacological products from plants and fungi. The Company also focuses on developing methodologies for the standardize and quality-controlled extraction of psychoactive compounds from plants and fungi, including Psilocybe spp. mushrooms; and the genera directive compounds, such as psilocybin, psilocin, and baeocystin, as well as the development of natural health care products from non-regulated compounds. The company was incorporated in 2020 and is based in Port Moody, Canada.
Metrics to compare | HAVN | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipHAVNPeersSector | |
---|---|---|---|---|
P/E Ratio | 0.0x | −5.3x | −0.5x | |
PEG Ratio | 0.00 | 0.02 | 0.00 | |
Price/Book | 0.0x | −0.8x | 2.6x | |
Price / LTM Sales | 0.0x | 2.7x | 3.3x | |
Upside (Analyst Target) | 0.0% | 145.6% | 43.5% | |
Fair Value Upside | Unlock | 5.0% | 6.9% | Unlock |